Cardiff Lexington Announces Fourth Quarter and Full Year 2025 Financial Results

About this update from Cardiff Lexington Corporation

Cardiff Lexington Announces Fourth Quarter and Full Year 2025 Financial Results Cardiff Lexington Announces Fourth Quarter and Full Year 2025 Financial Results 39.5% increase in FY25 total revenue to $11.5 million compared to FY 2024 62.7% increase in FY25 gross profit to $7.2 million compared to FY 2024 $1.1 million in income from continuing operations in FY 2025 Strengthening operational team and capital structure to position Company for next phase of growth LEXINGTON, KY / ACCESS Newswire / March 16, 2026 / Cardiff Lexington Corporation (OTCQB:CDIX) today announced financial results for the fourth quarter and full year ended December 31, 2025. Alex Cunningham, Chief Executive Officer of Cardiff Lexington, commented, "2025 was a year of strong strategic execution as we continued to enhance our Nova Ortho and Spine footprint and offerings while making meaningful progress on our long-term goals. Notably, full year revenue increased 39.5% on a GAAP basis in 2025 compared with 2024, supported by our operations in numerous diverse locations throughout Florida and Georgia where we are seeing strong demand for our services. Operationally, we've shifted our focus to more higher value surgical procedures, and our patient volumes continue to increase, with an average of between 270 and 375 patients treated per month across all our locations. "During the fourth quarter, we strengthened the Nova Ortho and Spine team with the addition of leading healthcare talent and entered a strategic partnership with Doctors' Memorial Hospital in Perry, Florida to bring our leading services to patients in this area of the state. Subsequent to the close of the quarter, we improved our capital structure with the execution of a 1-for-3 reverse split as a part of our planned uplisting to a major US stock exchange. We believe this will strengthen our capital markets profile and enhance our visibility, liquidity, and access to capital to support our anticipated growth as we continue to bring our world-class care to an underserved patient population," Mr. Cunningham concluded. Full Year 2025 Financial Highlights Total revenue increased 39.5% to $11.5 million compared with $8.3 million in full year 2024, primarily related to higher patient volume and a shift to more higher value surgical procedures throughout the year. Revenue in full year 2024 included one-time adjustments of $2.8 million. Non-GAAP adjusted revenue, which excludes this one-time adjustment to revenue, was $11.1 million for full year 2024. Gross profit increased to $7.2 million, or 62.5% of total revenue, compared with $4.4 million, or 53.6% of total revenue in full year 2024. Total operating expenses increased to $6.1 million compared with $4.6 million in full year 2024, primarily related to increased SG&A expense of $5.3 million, or 46.2% of revenue, compared with $4.1 million, or 49.1% of revenue, for the full year 2024. Operating income increased to $1.1 million, or 9.5% of total revenue, compared with operating loss of $(193,000), or (2.3%) of total revenue, in full year 2024. Net loss in full year 2025 was $(5.5 million) compared with net loss of $(3.3 million) in full year 2024. Included in full year 2025 was interest expense of $(6.8 million) compared with interest expense of $(3.0 million) in full year 2024. This increase in interest expense is primarily related to increases in initial and incremental fees charged on the number of existing purchases and claims under the Company's line of credit. Non-GAAP adjusted EBITDA, which excludes interest expense, was $1.8 million compared with non-GAAP adjusted EBITDA of $2.1 million in full year 2024, which excludes interest expense and the change in accounting estimate of the billing realization rate recognized in third quarter 2024. Fourth Quarter 2025 Financial Results Total revenue was $2.8 million compared with 3.1 million in the fourth quarter of 2024. The decrease is primarily attributed to normal variances around the collection cycle timeframe on accounts receivables, which is typically between 12 and 24 months, as well as the timing of the 2025 holiday season, which resulted in significantly reduced patient volume over the two-week period around Christmas and New Years. Gross profit was $1.8 million, or 63.5% of total revenue, compared with $2.0 million, or 64.8% of total revenue in the fourth quarter of 2024. Total operating expenses increased to $2.5 million compared with $1.7 million in the fourth quarter of 2024, primarily related to increased stock compensation expense of $616,000 and SG&A expense of $1.8 million, or 66.0% of revenue in the fourth quarter of 2025, compared with $1.4 million, or 46.2% of revenue in the fourth quarter of 2024. Loss from continuing operations was $(696,000), or (25.1%) of total revenue, in the fourth quarter of 2025, compared with income from continuing operations of $332,000, or 10.6% of total revenue, in the fourth quarter of 2024. Net loss in the fourth quarter of 2025 was $(2.7 million) compared with net loss of $(910,000) in the fourth quarter of 2024. Included in net loss for the three months ended December 31, 2025, was interest expense of $(2.2 million) compared with interest expense of $(1.2 million) in the fourth quarter of 2024. This increase in interest expense is related to increases in initial and incremental fees charged on the number of existing purchases and claims under the Company's line of credit. Non-GAAP adjusted EBITDA, which excludes interest expense, was a loss of $(79,000) compared with non-GAAP adjusted EBITDA of $579,000 in the fourth quarter of 2024. Balance Sheet Cash totaled $319,000 as of December 31, 2025. Total assets increased 21.6% to $29.1 million as of December 31, 2025. Conference Call Cardiff Lexington will hold a conference call and webcast for investors today, March 16, 2026, at 11:00 a.m. Eastern Time. Shareholders and interested parties may participate in the conference call by dialing (888) 506-0062 and international participants should dial (973) 528-0011 and use access code: 860308. The call and the accompanying slide deck will also be webcast at: https://www.webcaster5.com/Webcast/Page/3131/53650 The conference call and slide deck may also be accessed via the Investor Relations page of the Company's website at https://investor.cardifflexington.com/overview/default.aspx . Please allow extra time prior to the call to visit the site. An online archive of the webcast will be available on the Investor Relations page of the Company's website following the call at https://investor.cardifflexington.com/overview/default.aspx . A replay of the conference call will be available one hour after completion of the call until Monday, March 30, 2026, by dialing (877) 481-4010 and international participants should dial (919) 882-2331. All callers must use access code 53650 to access the replay. ----- About Cardiff Lexington Corporation: Cardiff Lexington Corporation (OTCQB:CDIX) is a targeted healthcare holding company dedicated to acquiring and building middle-market niche health care clinics, primarily in Orthopedics, Spine Care, and Pain Management. The Company's partnership-driven culture emphasizes service excellence, teamwork, accountability, and performance . All current revenue is derived from Nova Ortho and Spine, LLC , which operates a network of regional specialty and ancillary orthopedic care centers across Florida and Georgia. These facilities provide traumatic injury patients with comprehensive diagnostic and surgical services, primary care evaluations, interventional pain management, and specialty consultations. For more information on Cardiff Lexington Corporation, you may access the company's website at https://cardifflexington.com/ FORWARD LOOKING STATEMENT: This news release contains forward looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. These risks include the failure to meet schedule or performance requirements of the Company's business, the Company's liquidity position, the Company's ability to obtain new business, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties the forward-looking events referred to in this release might not occur. Use of Non-GAAP Financial Measures Cardiff Lexington Corporation prepares its consolidated financial statements in accordance with United States generally accepted accounting principles ("GAAP"). In addition to GAAP disclosures, this document contains financial information and measures considered to be "non-GAAP". These non-GAAP measures can be used in order to gain a more complete and accurate understanding of the Company's financial condition and results. Non-GAAP financial measures should be considered in conjunction with, and not as a substitute to GAAP financial measures. Cardiff Lexington Investor Relations [email protected] (800) 628-2100 ext. 705 or IMS Investor Relations [email protected] (203) 972-9200 CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2025, AND 2024 For the Three Months Ended For the Twelve Months Ended December 31, December 31, December 31, December 31, 2025 2024 2025 2024 Total revenue $ 2,772,263 $ 3,120,710 $ 11,535,577 $ 8,270,126 Total cost of sales 1,011,387 1,099,863 4,329,330 3,841,628 Gross profit 1,760,876 2,020,847 7,206,247 4,428,498 Operating expenses Depreciation expense 762 3,365 5,652 13,461 Loss on disposal of fixed assets 0 0 12,593 0 Stock compensation expense 615,787 244,500 754,475 544,725 Selling, general and administrative 1,840,631 1,440,835 5,332,941 4,063,816 Total operating expenses 2,457,180 1,688,700 6,105,661 4,622,002 (Loss) income from continuing operations (696,304 ) 332,147 1,100,586 (193,504 ) Other (expense) income: Other expense 0 (642 ) (22,147 ) (5,362 ) Gain on debt refinance, forgiveness and settlement 0 0 0 78,834 Penalties and fees 0 0 (1,500 ) (1,330 ) Interest expense (2,228,102 ) (1,241,847 ) (6,822,816 ) (3,045,504 ) Amortization of debt discounts 0 0 0 (24,821 ) Total other expense (2,228,102 ) (1,242,489 ) (6,846,463 ) (2,998,183 ) Net loss before discontinued operations (2,924,406 ) (910,342 ) (5,745,877 ) (3,191,687 ) Income (loss) from discontinued operations 238,285 0 238,285 (111,312 ) Net loss $ (2,686,121 ) $ (910,342 ) $ (5,507,592 ) $ (3,302,999 ) CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2025, AND DECEMBER 31, 2024 December 31, December 31, 2025 2024 ASSETS Current assets Cash $ 318,535 $ 1,188,185 Accounts receivable-net 22,070,954 15,934,490 Prepaid and other current assets 203,876 89,901 Total current assets 22,593,365 17,212,576 Property and equipment, net 2,953 21,198 Land 540,000 540,000 Goodwill 5,666,608 5,666,608 Right of use - assets 214,858 406,950 Due from related party 4,979 4,979 Other assets 64,182 73,368 Total assets 29,086,945 23,925,679 LIABILITIES, MEZZANINE EQUITY AND DEFICIENCY IN STOCKHOLDERS' (DEFICIT)/EQUITY Current liabilities Accounts payable and accrued expense 1,760,765 1,379,760 Accrued expenses - related parties 4,645,826 4,553,057 Accrued interest 707,574 429,200 Right of use - liability 178,524 223,330 Notes payable - current portion 125,774 312,180 Notes payable related parties 1,085,703 0 Line of credit 17,209,908 8,645,991 Convertible notes payable, net of debt discounts of $131,705 and $24,821, respectively 118,295 105,000 Net liabilities of discontinued operations 0 238,285 Total current liabilities 25,832,369 15,886,803 Other liabilities Notes payable 138,773 251,725 Operating lease liability - long term 42,976 185,877 Total liabilities 26,014,118 16,324,405 Mezzanine equity Redeemable Series N Senior Convertible Preferred Stock - 3,000,000 shares authorized, $0.001 par value, stated value $4.00, 1,037,311 and 921,636 shares issued and outstanding at December 31, 2025 and 2024, respectively 3,802,010 3,339,317 Redeemable Series X Senior Convertible Preferred Stock - 5,000,000 shares authorized, $0.001 par value, stated value of $4.00 par value; 438,388 and 397,464 shares issued and outstanding at December 31, 2025 and 2024, respectively 1,740,478 1,576,788 Total Mezzanine Equity 5,542,488 4,916,105 Stockholders' (deficit)/equity Series B Preferred Stock - 3,000,000 shares authorized, $0.001 par value, stated value of $4.00, 0 and 1,279,867 shares issued and outstanding at December 31, 2025 and 2024, respectively 0 5,119,468 Series C Preferred Stock - 500 shares authorized, $0.001 par value, stated value of $4.00, 0 and 74 shares issued and outstanding at December 31, 2025 and 2024, respectively 0 296 Series E Preferred Stock - 1,000,000 shares authorized, $0.001 par value, stated value $4.00, 0 and 175,375 shares issued and outstanding at December 31, 2025 and 2024, respectively 0 701,500 Series F-1 Preferred Stock - 50,000 shares authorized, $0.001 par value, stated value $4.00, 3,875 shares issued and outstanding at December 31, 2025 and 2024 15,500 15,500 Series I Preferred Stock - 15,000,000 shares authorized, $0.001 par value, stated value $4.00, 0 and 10,469,092 issued and outstanding at December 31, 2025 and 2024, respectively 0 41,876,368 Series L Preferred Stock - 400,000 shares authorized, $0.001 par value, stated value $4.00, 319,493 shares issued and outstanding at December 31, 2025 and 2024 1,277,972 1,277,972 Series Y Senior Convertible Preferred Stock - 1,500,000 shares authorized, $0.001 par value, stated value of $4.00, 1,067,878 and 979,125 shares issued and outstanding at December 31 2025 and 2024, respectively 4,271,512 3,916,500 Common Stock; 300,000,000 shares authorized, $0.001 par value; 13,701,698 and 15,300,475 shares issued and outstanding at December 31, 2025 and 2024, respectively 13,702 15,300 Additional paid-in capital 72,021,848 22,711,350 Unearned stock compensation (579,215 ) 0 Accumulated deficit (79,490,980 ) (72,949,085 Total stockholders' (deficit)/equity (2,469,661 ) 2,685,169 Total liabilities, mezzanine equity and stockholders' equity 29,086,945 23,925,679 CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES RECONCILIATION OF NON-GAAP FINANCIAL MEASURES FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2025, AND 2024 (Unaudited) The following table reconciles Net (loss) income before discontinued operations (a GAAP measure) to EBITDA (a non-GAAP measure) For the Three Months Ended For the Twelve Months Ended December 31, December 31, 2025 2024 2025 2024 EBITDA (1) Net loss before discontinued operations $ (2,924,406 ) $ (910,342 ) $ (5,745,877 ) $ (3,191,687 ) Add: Interest 2,228,102 1,241,847 6,822,816 3,045,504 Taxes 0 0 0 0 Depreciation 762 3,365 5,652 13,461 Amortization 0 0 0 24,821 EBITDA (1) $ (695,542 ) $ 334,870 $ 1,082,591 $ (107,901 ) Adjusted EBITDA (2) EBITDA $ (695,542 ) $ 334,870 $ 1,082,591 $ (107,901 ) Add: Change in estimate for settlement realization rate 0 0 0 1,650,474 Stock compensation expense for shares issued 615,787 244,500 754,475 544,725 Adjusted EBITDA (2) $ (79,755 ) $ 579,370 $ 1,837,066 $ 2,087,298 Adjusted EBITDA excluding other non-recurring costs (3) Adjusted EBITDA $ (79,755 ) $ 579,370 $ 1,837,066 $ 2,087,298 Add: Scaling and restructuring costs for business growth 473,804 39,752 485,480 220,053 Acquisition related costs 59,256 30,581 230,771 30,581 Adjusted EBITDA excluding other non-recurring costs (3) $ 453,305 $ 649,702 $ 2,553,317 $ 2,337,932 (1) EBITDA is a non-GAAP financial measure defined as Earnings Before Interest, Income Tax, Depreciation and Amortization. (2) Adjusted EBITDA is a non-GAAP financial measure that is the sum of EBITDA plus non-recurring and non-cash charges. (3) Adjusted EBITDA excluding other non-recurring costs is a non-GAAP financial measure that is the sum of Adjusted EBITDA plus other non-recurring costs. CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES RECONCILIATION OF REVENUE FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2025, AND 2024 The following table reconciles Revenue (a GAAP financial measure) to Adjusted Revenue (non-GAAP financial measures) For the Three Months Ended December 31, For the Twelve Months Ended December 31, 2025 2024 2025 2024 GAAP Revenue $ 2,772,263 $ 3,120,710 $ 11,535,577 $ 8,270,126 Adjustments to Claim Settlement Realization Rate - - - 2,849,629 Non-GAAP Adjusted Revenue $ 2,772,263 $ 3,120,710 $ 11,535,577 $ 11,119,755 SOURCE: Cardiff Lexington Corporation View the original press release on ACCESS Newswire https://app.accessnewswire.com/img.ashx?id=1147847 © Copyright 2026 ACCESS Newswire. All Rights Reserved.

View stock analysis, news, and events for Cardiff Lexington Corporation